Fortis Healthcare Ltd NSE  /  BSE

Healthcare, Mid Cap

27 Nov 2020 | 03:59 PM

151.10
3.05 (2.06%)

Independent Research

theScreeners

We bring you Independent research views from famous names like Reuters and theScreeners to help improve your investing results and create wealth

Star Rating

Initiated on 01-01-70

Target Price

Performance parameters

  • Earnings Revision Trend

    Analysts negative since 03-Apr-2020

    Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 03-Apr-2020 at a price of 122.15.

  • Valuation Rating

    Strongly undervalued

    Based on its growth potential and our own criteria, at its current price the stock is strongly undervalued.

  • MT Tech Trend

    Trend negative since 10-Mar-2020

    The forty day Medium Term Technical Trend is negative since 10-Mar-2020. The confirmed Technical Reverse point (Tech Reverse + 1.75%) is 132.250.

  • 4W REL Performance

    Under pressure (vs. SENSEX30)

    The four week relative underperformance versus SENSEX30 is -14.500.

Risk parameters

  • Risk Zone

    Low

    The stock has been on the low-sensitivity level since 20-Mar-2020.

  • Bear Market

    Below average sensitivity to market corrections

    On average, the stock has a tendency to minimize the drops in the index by -72%.

  • Bad News

    Slight market sanction in case of specific pressure

    When the stock's pressure is specific, the market sanction on average is 285%.

  • Beta

    40 Low sensitivity to SENSEX30

    For 1% of index variation, the stock varies on average by 40%.

  • Correlation

    0.38 Weak correlation to SENSEX30

    Stock movements are strongly independent of index variations.

  • Value at Risk

    Rs.9.94 The medium term value at risk is estimated at 9.94 or 0.07829%

    The value at risk is estimated at 9.94. The risk is therefore 0.07829%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.

Other parameters

  • LT Growth

    40.99 Current year to 2022 annualized estimate

    The annualized growth estimate is for the current year to 2022.

  • P/E Ratio

    33.43 Estimated PE for 2022

    The estimated PE is for the year 2022.

  • G/PE Ratio

    1.23 26.605% discount to expected growth

    A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of 26.605%.

  • Dividend Yield

    0% Dividend is largely covered by profits

    The twelve month estimated dividend yield represents 0.142% of earnings forecasts.

  • Global Evaluation

    Slightly positive

    The stock is classified in the slightly positive zone since 17-Apr-2020.